Close
Help
signup_email_alerts
Need Help?



Quality of Life and Neutropenia in Patients with Early Stage Breast Cancer: A Randomized Pilot Study Comparing Additional Treatment with Mistletoe Extract to Chemotherapy Alone

Submit a Paper


Libertas Analytics


4242 Article Views

Publication Date: 06 Jul 2009

Journal: Breast Cancer: Basic and Clinical Research

Citation: Breast Cancer: Basic and Clinical Research 2009:3 35-45

BCbcr journal

144,100 Article Views

6,649,582 Libertas Article Views

More Statistics

Abstract

Background: Chemotherapy for breast cancer often deteriorates quality of life, augments fatigue, and induces neutropenia. Mistletoe preparations are frequently used by cancer patients in Central Europe. Physicians have reported better quality of life in breast cancer patients additionally treated with mistletoe preparations during chemotherapy. Mistletoe preparations also have immunostimulant properties and might therefore have protective effects against chemotherapy-induced neutropenia.

Patients and Methods: We conducted a prospective randomized open label pilot study with 95 patients randomized into three groups. Two groups received Iscador® M special (IMS) or a different mistletoe preparation, respectively, additionally to chemotherapy with six cycles of cyclophosphamide, adriamycin, and 5-fluoro-uracil (CAF). A control group received CAF with no additional therapy. Here we report the comparison IMS (n = 30) vs. control (n = 31). Quality of life including fatigue was assessed with the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30). Neutropenia was defined as neutrophil counts <1,000/µl and assessed at baseline and one day before each CAF cycle.

Results: In the descriptive analysis all 15 scores of the EORTC-QLQ-C30 showed better quality of life in the IMS group compared to the control group. In 12 scores the differences were significant (p < 0.02) and nine scores showed a clinically relevant and significant difference of at least 5 points. Neutropenia occurred in 3/30 IMS patients and in 8/31 control patients (p = 0.182).

Conclusions: This pilot study showed an improvement of quality of life by treating breast cancer patients with IMS additionally to CAF. CAF-induced neutropenia showed a trend to lower frequency in the IMS group.


Post a Comment

x close

Discussion Add A Comment
No comments yet...Be the first to comment.


share on

Our Service Promise

  • Prompt Processing (Less Than 3 Weeks)
  • Fair & Comprehensive Peer Review
  • Professional Author Service
  • Leading Editors in Chief
  • Extensive Indexing
  • High Readership & Impact
  • What Your Colleagues Say

Quick Links

Follow Us We make it easy to find new research papers. RSS Feeds Email Alerts Twitter

BROWSE CATEGORIES
Our Testimonials
I have to say this was one of my most pleasant and friendly experiences as a peer reviewer. The clear and straight-forward requirements of Ophthalmology and Eye Diseases is a breath of fresh air in peer reviewing.
Dr Lampros Panagis (SUNY Downstate Medical Center, Brooklyn, NY, USA ) What Your Colleagues Say